The wound management formulary has been developed by the Joint Wound Management Formulary Group. Please use the links below to navigate to the relevant sections.
|1||Introduction||10||Choosing the ideal dressing|
|2||Wound healing process||11||Guidelines for good practice in the management of wounds|
|3||Wound types and categorisation||12||Dressing selection chart|
|4||Assessment||13||Information on products included in the formulary|
|5||Factors delaying wound healing||14||Specialised dressings|
|6||Wound colonisation/clinical infection||15||Challenging wounds|
|8||Nutrition and hydration||17||Glossary|
|1||Non-formulary exception reporting form|
|2||SWYAPC Wound Care Formulary – Handheld List – August 2016 – minor changes 01.05.2018 – added pack size for Debrisoft Lolly|
|3||Local wound assessment tool – obtain from individual organisations|
|4||Wound dressing request form|
|5||Evaluation of wound care products|
|6||Topical antimicrobial – including advice on the use of silver dressings – updated 21.04.2017|
|7||Wakefield Wound Care Product order Form|
*Patients should be encouraged to self-care where appropriate. Practitioners’ responsibilities include a self-care risk assessment, providing patient information leaflets and advising about red flags and when these need to be escalated, and how*.
Wound Care Bulletins
Quick Reference Guides
Public Health England (PHE)
PHE notes in it’s guidance on primary care infections that widespread use of topical antibiotics, especially those agents also available systemically, is to be avoided. If use is indicated topical use should be limited in most cases.
Paraffin-containing skin preparations (emollients)
BBC News Health has recently highlighted the dangers of using paraffin-containing skin preparations whilst smoking or using naked flames. For further information see this document and leaflet which include advice for both healthcare professionals and patients.
Advice on diamorphine and intrasite gel
The CDAO are aware of the unlicensed use of Intrasite gel and Diamorphine Injection in certain settings.
The decision to use this would be a clinical judgement for the individual prescriber.
In all cases, if this is the chosen treatment, both the person administering the treatment, and the patient, must be aware of its unlicensed status. There must also be a full audit trail for the use of the Diamorphine (including destruction details of any part ampoules that may have been discarded)
Regarding treatment suitability and evidence please contact the Yorkshire Cancer Network
Formulary produced by: Joint Wound Management Formulary Group
Original date: March 2008
First review: March 2010
Second review: April 2012
Third review: July 2015
Fourth review: May 2016
Originally approved by SWY Area Prescribing Committee: 28 March 2008.